Life sciences tools bioproduction reported revenue growth contribution measures how much disclosed bioproduction revenue growth contributes to reported growth in Thermo Fisher Scientific's Life Sciences Solutions segment.
Thermo Fisher said bioproduction revenue increased $196M in the second quarter of 2026 and contributed 8 percentage points of reported segment growth.
Demand and acquisition effects both contributed
The company attributed the increase to stronger pharma and biotech demand as well as the 2025 acquisition of a filtration and separation business.
The contribution therefore should not be read as an organic bioproduction growth rate.
Contribution helps explain the reported-organic gap
Life Sciences Solutions reported 13% revenue growth but only 3% organic growth in the quarter because acquisitions and currency also affected the reported result.
Use the contribution with Life Sciences Solutions organic revenue growth and Life Sciences Solutions segment income margin.
Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.
Part of the Life Sciences Tools & Biopharma Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- TMOOpen operating-model research →10 of 10 reviewed concepts in Life Sciences Tools & Biopharma Services EconomicsReported business-growth contribution2 of 2 bridge concepts supportedContinue through this bridge:Clinical Research Growth Contribution
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare bioproduction growth contributions
Compare disclosed bioproduction contributions to reported growth without relabeling acquisition-influenced growth as organic demand.
Explore more topics in the Financial Research Encyclopedia.